Access to Study Data. Subject to the provisions of Sections 8.1, each Party shall have access to all Combined Therapy Study Data, Recipient Study Data and BMS Study Data (including de-identified patient records). The relevant Party shall make such Study Data in its possession available to the other Party within a reasonable period, not to exceed [ ]*, after such Study Data is available to or generated by the applicable Party.
Appears in 3 contracts
Samples: Clinical Trial Collaboration and Supply Agreement (Replimune Group, Inc.), Clinical Trial Collaboration and Supply Agreement (Replimune Group, Inc.), Clinical Trial Collaboration and Supply Agreement (Replimune Group, Inc.)
Access to Study Data. Subject to the provisions of Sections 8.1, each Party shall have access to all Combined Therapy Study Data, Recipient Study Data and BMS Study Data (including de-identified patient records). The relevant Party Recipient shall make such Study Data in its possession available to the other Party BMS within a reasonable period, not to exceed [ [**]*, after such Study Data is available to or generated by the applicable PartyRecipient.
Appears in 2 contracts
Samples: Trial Collaboration and Supply Agreement (Idera Pharmaceuticals, Inc.), Clinical Trial Collaboration and Supply Agreement (Idera Pharmaceuticals, Inc.)
Access to Study Data. Subject to the provisions of Sections 8.1, each Party shall have access to all Combined Therapy Study Data, Recipient Study Data and BMS Study Data (including de-identified patient records). The relevant Party shall make such Study Data in its possession available to the other Party within a reasonable period, not to exceed [ [***]*, after such Study Data is available to or generated by the applicable Party.
Appears in 1 contract
Samples: Collaboration and Supply Agreement (Replimune Group, Inc.)
